Although post-IVT sICH is an ominous event, a key clinical question remains whether the presence or burden of CMBs Background and Purpose-Whether cerebral microbleeds (CMBs) detected on pretreatment magnetic resonance imaging increase the risks of symptomatic intracranial hemorrhage (sICH) and, most importantly, poor outcome in patients treated by intravenous thrombolysis for acute ischemic stroke is still debated. We assessed the effect of CMB presence and burden on 3-month modified Rankin Scale and sICH in a multicentric cohort. Methods-We analyzed prospectively collected data of consecutive patients solely treated by intravenous thrombolysis for acute ischemic stroke, in 2 centers where magnetic resonance imaging is the first-line pretreatment imaging. Neuroradiologists blinded to clinical data rated CMBs on T2* sequence using a validated scale. Logistic regressions were used to assess relationships between CMBs and 3-month modified Rankin Scale or sICH. Results-Among 717 patients, 150 (20.9%) had ≥1 CMBs. CMB burden was associated with worse modified Rankin Scale in univariable shift analysis (odds ratio, 1.07; 95% confidence interval, 1.00-1.15 per 1-CMB increase; P=0.049), but significance was lost after adjustment for age, hypertension, and atrial fibrillation (odds ratio, 1.03; 95% confidence interval, 0.96-1.11 per 1-CMB increase; P=0.37). Results remained nonsignificant when taking into account CMB location or presumed underlying vasculopathy. The incidence of sICH ranged from 3.8% to 9.1%, depending on the definition. Neither CMB presence, burden, location, nor presumed underlying vasculopathy was independently associated with sICH. Conclusions-Poor outcome or sICH was not associated with CMB presence or burden on pre-intravenous thrombolysis magnetic resonance imaging after adjustment for confounding factors. An individual patient data meta-analysis is needed to determine whether a subgroup of patients with CMBs carries an independent risk of poor outcome that might outweigh the expected benefit of intravenous thrombolysis. 
See related article, p 2403. C erebral microbleeds (CMBs) are small areas of signal void on T2* or susceptibility-weighted imaging (SWI), which correspond to focal hemosiderin deposits presumably due to previous leakage from small vessels. 1, 2 In patients with acute ischemic stroke (AIS), the reported prevalence of CMBs on pretreatment magnetic resonance imaging (MRI) ranges from 15% to 35%, depending on cohort characteristics and MRI sequences (T2* or SWI). [3] [4] [5] Whether preexisting CMBs increase the risks of intravenous thrombolysis (IVT)-related symptomatic intracranial hemorrhage (sICH) and, most importantly, of poor functional outcome is still uncertain. 6 Several studies have assessed the potential association between CMBs and post-IVT sICH, with conflicting results, which prevented the American Heart Association Stroke Council from making specific recommendations on IVT in patients with CMBs. 7 In 2013, 2 independent systematic reviews and meta-analyses found an ≈2-fold increased risk of sICH in patients with ≥1 CMB on pre-IVT MRI, but this association failed to reach statistical significance. 8, 9 In view of the methodological limitations and heterogeneity of the included studies, namely different study designs, treatment modalities, and definitions of sICH, authors acknowledged that good quality data from large, prospective cohorts were lacking at that time. 10 In 2014 and 2015, 3 additional studies reported results from prospectively collected data. Two found a significant association between CMB presence (or burden) and post-IVT sICH, 5, 11 whereas the last one did not.
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on-pretreatment MRI independently increases the risk of poor long-term outcome after IVT. Indeed, the benefit of IVT at 3 months may outweigh its harms even in some patients with initial sICH. We aimed to determine whether the presence and burden of CMBs on pretreatment MRI were independently associated with 3-month outcome and sICH.
Materials and Methods

Patients
We analyzed prospectively collected data of consecutive patients who underwent IVT for AIS in 2 French centers where MRI is the first-line pretreatment imaging for AIS (Sainte-Anne, Paris, November 2003 to December 2013 and Lille, October 2009 to May 2014). Patients were included (1) if they had a pretreatment MRI, including diagnostic quality T2* sequence, and (2) if they were treated by IVT alone (alteplase, 0.9 mg/kg) for an AIS <4.5 hours or for a wake-up stroke with diffusion-weighted imaging fluid-attenuated inversion recovery mismatch. 12, 13 High CMB burden was not an exclusion criterion for IVT in both centers. Sex, age, history of hypertension, diabetes mellitus, current smoking, atrial fibrillation, previous stroke/transient ischemic attack, baseline National Institute of Health Stroke Scale (NIHSS) score, serum glucose, blood pressure before IVT, and onsetto-treatment time were routinely collected.
In accordance with the French legislation, the study did not need approval by an Ethics Committee nor written informed consent from patients because it implied only analysis of anonymized data collected prospectively as part of routine clinical care. The article was prepared in accordance with recently proposed recommendations for studies investigating the association between CMBs and sICH or 3-month outcome. 
Imaging Methods and Definition of CMBs
In both centers, pretreatment MRI included diffusion-weighted imaging, fluid-attenuated inversion recovery, T2*-weighted gradient echo imaging, and intracranial MR angiography (total acquisition time, ≤10 minutes). The acquisition parameters of the T2* sequences remained unchanged throughout the study period: (1) Sainte-Anne center (1. 34 A follow-up imaging (MRI including T2* sequence or computed tomographic scanner) was scheduled ≈24 hours after IVT and in the case of neurological deterioration.
Pretreatment T2* images were rated by neuroradiologists, blinded to clinical and follow-up imaging data, for the number of CMBs and their distribution, according to a validated scale.
14 CMBs were defined as small areas (≤10 mm) of signal void on T2* sequence with associated blooming and were classified as lobar, deep, or infratentorial. 14, 15 All available MR sequences were analyzed to exclude potential CMB mimics (vascular structures, thrombus, calcifications, iron deposits, cavernous malformation, or hemorrhagic metastases). 15, 16 Presumed underlying vasculopathy for CMBs was defined as cerebral amyloid angiopathy (CAA: strictly lobar distribution of CMBs in patients aged ≥55 years), 5, 17 hypertensive vasculopathy (strictly deep or infratentorial distribution of CMBs in hypertensive patients), 4 or undetermined (all other situations). 5 Existence of ICH according to published radiological classification criteria (hemorrhagic infarct or parenchymal hematoma, type 1 or 2) 18 was rated on follow-up images by neuroradiologists blinded to clinical data and pretreatment CMB status.
Outcomes
Functional outcome (3-month modified Rankin Scale [mRS]) was considered as the primary end point and prospectively assessed by board-certified stroke neurologists, blinded to CMB rating, during face-to-face visits or structured telephone interviews. Occurrence of sICH was considered as the secondary end point and assessed according to 4 definitions ( 
Statistical Analysis
Continuous variables were expressed as mean±SD or median (interquartile range) and compared using the t test or Mann-Whitney U test, as appropriate. Categorical variables were expressed as percentages and compared using the Pearson χ 2 test or Fisher's exact test, as appropriate. Associations between CMBs (presence or burden) and dependent variables (3-month mRS or sICH according to the 4 above-mentioned definitions) were assessed by calculations of crude and adjusted odds ratios (OR) and 95% confidence intervals (CI) in logistic regression models. Baseline variables associated with CMB presence at a level of P<0.20 in univariable analysis were considered for inclusion into multivariable models, taking into account potential multicollinearity. CMB burden was examined as a continuous variable (per 1-CMB increase) for the main analysis. In sensitivity analysis, CMB burden was examined using the following categorization: 0 versus 1 versus 2 to 4 versus ≥5.
5 Three-month mRS was dichotomized in binary logistic regression models (mRS score >1 versus ≤1
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; mRS score >2 versus ≤2 4 ). Because it may increase statistical power, 23 shift analysis over the whole range of the mRS was also performed in ordinal logistic regression models. For multivariable ordinal logistic regression, partial proportional odds models were used because 2 explanatory variables (age and hypertension) did not meet the assumption of proportional odds. 24 Statistical significance was set at P<0.05. Statistical analysis was performed using SAS version 9.4 (SAS Institute, Inc, Cary, NC).
Results
During the study period, 931 patients were treated by IVT for an ischemic stroke, of which 214 (23.0%) were excluded ( Figure I in the online-only Data Supplement), leaving 717 patients for the analysis (Lille, n=375; Sainte-Anne, n=342). Included and excluded patients did not differ on baseline characteristics, except for NIHSS score (median, 11 versus 14; P=0.01).
Patients' characteristics are summarized in Table 1 . Median (interquartile range) age and NIHSS score were 74 (60-83) and 11 (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) , respectively. Ninety-one (12.7%) patients had a prestroke mRS score >1, including 62 (8.6%) patients with a prestroke mRS score >2. On pretreatment imaging, 150 (20.9%) patients had ≥1 CMB (maximum 26); 92 (12.8%) had precisely 1 CMB, 33 (4.6%) had 2 to 4 CMBs, and 25 (3.5%) had ≥5 CMBs. The prevalence of CMBs did not differ across centers (P=0.78). Among patients with CMBs, presumed underlying vasculopathy was CAA in 60 (40.0%), hypertensive vasculopathy in 34 (22.7%), and undetermined in 56 (37.3%) patients. Associations between the presence of CMBs and baseline characteristics are summarized in Table 2 . Follow-up imaging modality was MRI in 674 (94.0%) patients.
At 3 months, 329 (45.9%) patients had a mRS score >2 and 434 (60.5%) had a mRS score >1. With such dichotomizations of the mRS score, there was no significant association between CMB presence or burden and 3-month outcome in univariable and multivariable analyses (Table 3) .
Shift analysis over the entire range of the mRS showed a marginally significant association between CMB burden (data not shown).
The rates of sICH ranged from 3.8% (ECASS-3 and SITS-MOST definitions) to 9.1% (NINDS definition). There was no significant association between CMB presence or burden (considered as a continuous variable) and sICH in univariable or multivariable analysis, irrespective of the sICH definition (Table 3) . In sensitivity analyses, CMB burden, considered as a categorical variable, was only marginally associated in univariable analysis with sICH according to the NINDS definition (P=0.046). CMB location or presumed underlying vasculopathy were not significantly associated with sICH (data not shown).
Discussion
Capitalizing on a large sample of patients with AIS to address the clinical relevance of CMBs on pre-IVT MRI, we observed a marginally significant association between CMB burden and worse 3-month outcome in univariable ordinal logistic regression, which lost significance after adjustment for confounding factors. We found no independent association between CMB burden at baseline and sICH, irrespective of the definition used.
Most researchers assessing the clinical significance of pre-IVT CMBs have focused on sICH, 3, 8 as this association has pathophysiological plausibility 10 and because sICH is a determinant cause of poor long-term functional outcome. 26 Although our findings on the relationship between sICH and CMB burden were similar to those of the previous reports, 3, 4 they stand in clear distinction to those of 2 recent studies. 5, 11 Using the ECASS-3 definition, both studies found a significant association between sICH and a high CMB burden. We could not replicate these findings, except in univariable analysis for sICH according to the NINDS definition, when using the specific categorization proposed by Dannenberg et al. This discrepancy is unlikely to be due to a lack of statistical power in our study, given its sample size and the prevalence of sICH, CMB presence, and proportion of patients with a high CMB burden, which were similar to those of the literature. [3] [4] [5] 8 Yet, differences in population characteristics could possibly explain the discrepancy across studies. Compared with our population, patients included in the study by Dannenberg et al 5 were slightly older and more frequently had a presumed CAA, which might carry a higher risk of post-IVT sICH, including remote parenchymal hematoma. 27 Although the proportion of presumed CAA in the subgroup of patients with ≥5 CMBs is not mentioned in the publication by Dannenberg et al, 5 it might have been higher than ours. Patients included in the study by Yan et al 11 had a high proportion of patients with ≥1 CMBs (39.9%) and an important CMB burden (742 CMBs in 133 patients), which is consistent with a previous report from another Asian cohort 28 but much higher than expected in a white one (401 CMBs in 150 patients in our study, in line with others 3 ). It remains to be determined whether Asian patients carry a higher risk of post-IVT sICH in the presence of CMBs than Western patients. 27 Although sICH is an important end point for patients with CMBs treated by IVT, our main end point was 3-month mRS, for several reasons. First, the incidence of sICH varies greatly depending on its definition, 22 none being optimal. 29, 30 By contrast, 3-month mRS is a consensual, reproducible, and widely used measure of long-term functional outcome. Second, the clinical relevance of CMB burden on pretreatment MRI should be assessed taking into account the long-term outcome, as the benefit of IVT at 3 months may outweigh its harms even in patients with initial sICH.
To date, 4 studies (including the present one) assessed the relationship between pre-IVT CMBs and 3-month outcome (Table II in the online-only Data Supplement) . 4, 5, 11 We found an association between CMB burden and worse outcome in univariable shift analysis, in line with findings from the 3 other above-mentioned studies. However, this unadjusted association could be because of confounding factors, such as older age [3] [4] [5] or hypertension. 4, 31 Indeed, in multivariable shift analysis, the association between CMB burden and worse outcome was no longer significant in our population, in line with previous findings. 4, 5 To date, only Yan et al 11 have observed a significant association between a high CMB burden and poor outcome in multivariable analysis. These conflicting results stress the need for an individual patient data meta-analysis to determine whether CMB burden is an independent predictor of 3-month poor outcome and to estimate the effect size of the association. Such a meta-analysis could yield sufficient statistical power to identify whether there is a subgroup of patients with CMBs, which seems to have an independent risk of poor 3-month outcome so important that it might outweigh the expected benefit of IVT. If such a subgroup exists, such findings would support a widespread use of MRI for AIS and could lead to a randomized controlled trial to determine the best acute treatment for these high-risk patients. However, to date, detecting CMBs on pretreatment MRI should not prevent IVT based on current evidence, given the uncertainty about the independence of the association between CMBs and poor outcome, and the lack of a control (placebo) group in the available observational studies.
Strengths of our study include its sample size, the prospective data collection involving 2 centers, the systematic implementation of MRI as first-line pretreatment imaging in both centers, the use of a validated scale for CMBs rating, 14 and the homogeneity of the cohort, as only patients solely treated by IVT were included. Our study has several potential limitations. First, 23% of the patients treated by IVT during the study period were excluded from the final analysis. However, included and excluded patients did not differ on baseline characteristics except for NIHSS score, which was not associated with CMB presence or burden in our or in previous studies. [3] [4] [5] 28 Second, the lack of a control group without IVT prevented us from drawing conclusions on the benefit/risk ratio of IVT in subgroups of interest. However, withholding IVT in patients otherwise eligible for this treatment may be ethically questionable. 3 Third, the statistical power of our study was limited for : T2*/3T; Yan et al 11 : SWI/3T). However, other researchers, using SWI (1.5T and 3T) did not find such an association. 4 The magnetic field strength does not greatly modify the detection of CMBs, 4 but SWI is more sensitive than T2* for detecting CMBs. 32 Using the T2* instead of SWI sequence, we may have underestimated the global number of CMBs, which only plausible consequence would be a loss of statistical power. Of note, despite using different T2* parameters, the prevalence of CMBs was similar across our centers.
In conclusion, we found that CMB burden on pre-IVT MRI was not associated with an increased risk of poor 3-month outcome after adjustment for confounding factors, such as age and hypertension. An individual patient data metaanalysis is needed to determine whether a subgroup of patients with CMBs carries an independent risk of 3-month poor outcome that might outweigh the expected benefit of reperfusion therapies. 
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